menu
    • menu

    Company profile for Leveragen

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Leveragen, based in Boston, is a biotech company at the forefront of genetic engineering. We offer integrated solutions for genetic modeling, focusing on creating tailored mutations to investigate gene functions and disease mechanisms. Our current efforts are directed toward developing advanced genetic models to uncover a wide range of biological modalities, which supports the innovation of novel diagnostics and therapeutics.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    LeveragenUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2-F Gill Street Woburn, Massachusetts 01801
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://leveragen.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/leveragen/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Leveragen, Daiichi Sankyo Partner on In Vivo Antibody Platforms
    Leveragen, Daiichi Sankyo Partner on In Vivo Antibody Platforms

    18 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-18/leveragen-announces-collaboration-with-daiichi-sankyo-to-support-development-of-advanced-biologics-u

    PHARMIWEB
    18 Mar 2026
    Share Share
    Leveragen, Propeller Bio Partner on Biologic Therapies
    Leveragen, Propeller Bio Partner on Biologic Therapies

    25 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250725545759/en/Leveragen-and-Propeller-Bio-Announce-Strategic-Collaboration-to-Advance-Antibody-and-Protein-Therapeutics

    BUSINESSWIRE
    25 Jul 2025
    Share Share
    Leveragen partners with Cell Signaling for Nanobody Technology
    Leveragen partners with Cell Signaling for Nanobody Technology

    25 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250325009806/en/Leveragen-Partners-with-Cell-Signaling-Technology-to-Advance-Reagent-Antibody-Innovation-with-Proprietary-Nanobody-Technology

    BUSINESSWIRE
    25 Mar 2025
    Share Share
    Leveragen, Moonlight Bio Partner On T Cell Therapies
    Leveragen, Moonlight Bio Partner On T Cell Therapies

    29 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250129572363/en

    BUSINESSWIRE
    29 Jan 2025
    Share Share
    Antibody Solutions Approved as CRO for Leveragen’s Singularity Mouse
    Antibody Solutions Approved as CRO for Leveragen’s Singularity Mouse

    14 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241114041971/en

    BUSINESSWIRE
    14 Nov 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search